Please ensure Javascript is enabled for purposes of website accessibility

Is OrganiGram Holdings a Buy?

By Zhiyuan Sun - Apr 20, 2021 at 6:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This under-the-radar Canadian pot grower is underwater.

Over the past month, OrganiGram Holdings (OGI 1.53%) has seen its share price collapse by nearly 33%. Investors' hype about its potential evaporated when the company released its latest quarterly earnings.

While Canada's provincial lockdown measures to contain the coronavirus impacted marijuana stores' bottom line in the first quarter of 2021, OrganiGram had huge problems with its business model before such containment methods even began. Let's look at why marijuana investors should stay well away from this stock.

Man inspecting marijuana plant with a magnifying glass.

Image source: Getty Images.

Dreadful results

During Q2 2021 (ended Feb. 28), OrganiGram's net revenue decreased by 37% year over year to just 14.64 million Canadian dollars. The decline is the result of lower prices for pot, lower wholesale volume, and a lack of brand popularity. Over the past year, the company launched 62 new products, and has an additional 31 ready to go by the end of next quarter. Even that effort wasn't enough to lift its falling sales.

Simultaneously, the company's gross profit amounted to negative CA$17.195 million, compared to a gain of CA$11.288 million in the prior-year's quarter. OrganiGram simply had too much pot in its inventory and had to write it off as losses when it couldn't sell all of it.

In fact, the company sold just 3,688 kilograms of dried cannabis in Q2 2021, a 10% decline compared to the prior-year's quarter. Back in 2019, OrganiGram invested in state-of-the-art facilities that would produce up to 76,000 kg of cannabis per year. The demand needed to fulfill that supply has not materialized.

Right now, Canadian pot growers have stockpiled a total of 1.1 million kilograms of pot -- equivalent to about three years of consumption as the market enters the oversupply phase. In turn, the oversupply is driving down prices and causing huge losses to companies that expanded too quickly, like OrganiGram. The company's net losses increased by as much as 872% year over year in the quarter, to CA$66.389 million, or 4.53 times its revenue.

Can OrganiGram stage a comeback?

OrganiGram eliminated its debt through equity financing rounds and ended up with CA$232 million of cash on its balance sheet as of Feb. 28. On March 11, a British American Tobacco subsidiary purchased a CA$221 million stake in the company in exchange for 20% equity. Theoretically, the two could leverage their partnership and expertise to jointly develop products such as cannabidiol (CBD) hemp cigarettes with the new capital. Although, OrganiGram's focus seems to be elsewhere. Not even a month later, the company paid CA$22 million to acquire The Edibles & Infusion Corp in order to gain exposure to the Canadian edibles market.

The problem with these financing efforts is that they came at a time when OrganiGram's losses are accelerating, and the business doesn't even have profitability in sight. Under such conditions, investors should expect the company's net assets to dwindle over the time. By spending its cash on financing other marijuana firms instead of fixing its operations, any returns from those ventures would likely be years away, if they were to arise at all.

Moreover, acquiring companies in a hyper-saturated market isn't going to propel Organigram's growth forward. At the moment, there's a ton of money to be made in the maverick U.S. marijuana market. Unfortunately, OrganiGram has no exposure to it.

What's the verdict?

With declining sales, huge losses, and no sign of a turnaround, OrganiGram stock is hardly worth the price while trading at 9.8 times revenue. I'd highly recommend checking out U.S. cannabis producer stocks that are growing their sales by over 100%, and trading for better levels.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OrganiGram Holdings Stock Quote
OrganiGram Holdings
OGI
$0.95 (1.53%) $0.01
British American Tobacco p.l.c. Stock Quote
British American Tobacco p.l.c.
BTI
$41.26 (-4.67%) $-2.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.